Pflanz Sandra, Brookman-Amissah Sabine, Roigas Jan, Kendel Friederike, Hoschke Bernd, May Matthias
Department of Urology, Carl-Thiem Hospital, Cottbus, Germany.
Scand J Urol Nephrol. 2008;42(6):507-13. doi: 10.1080/00365590802460633.
The determination of further prognostic factors is essential for the establishment of risk groups for patients with surgically treated renal cell carcinoma (RCC). The objective of this study was to validate the prognostic value of macroscopic tumour necrosis, concerning postoperative survival.
A total of 607 patients (387 men, 220 women), who had undergone surgical treatment for RCC, was retrospectively reviewed. Necrotic areas in the tumour were identified macroscopically followed by microscopic confirmation. Cancer-specific survival (CSS) and overall survival (OS) were estimated using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards regression models were fitted to determine associations between tumour necrosis, clinical and pathological features, and survival. In 447 patients who were still alive at the end of the study, median follow-up was 66 months (mean 71.2 months).
Tumour necrosis was identified in 25.5% of patients (n=155). After 5 years, CSS and OS in the group of patients with tumour necrosis amounted to 77.0% and 64.4%, respectively, compared with 89.8%and 81.9% in the group of patients without tumour necrosis (in each case p<0.001). Patients with tumour necrosis significantly more often showed a metastatic stage, lymph-node involvement, a higher pathological tumour stage, a higher grading and a larger tumour size. In addition, a more frequent appearance of microvascular invasion and thrombocytosis could be proven in patients with tumour necrosis in comparison to patients without these histopathological findings. On multivariate regression analysis, only metastatic stage, lymph-node involvement, platelet count >400/nl and tumour necrosis remained significant for survival (CSS, OS).
According to the results, tumour necrosis may be a useful factor in the prognostic assessment of patients with RCC. The integration of this parameter in prognostic models for postoperative survival is recommended.
确定更多的预后因素对于建立接受手术治疗的肾细胞癌(RCC)患者的风险分组至关重要。本研究的目的是验证大体肿瘤坏死对术后生存的预后价值。
回顾性分析了607例接受RCC手术治疗的患者(387例男性,220例女性)。肉眼识别肿瘤中的坏死区域,随后进行显微镜确认。采用Kaplan-Meier法估计癌症特异性生存(CSS)和总生存(OS)。使用单变量和多变量Cox比例风险回归模型来确定肿瘤坏死、临床和病理特征与生存之间的关联。在研究结束时仍存活的447例患者中,中位随访时间为66个月(平均71.2个月)。
25.5%的患者(n = 155)存在肿瘤坏死。5年后,有肿瘤坏死的患者组的CSS和OS分别为77.0%和64.4%,而无肿瘤坏死的患者组分别为89.8%和81.9%(每种情况p < 0.001)。有肿瘤坏死的患者更常出现转移阶段、淋巴结受累、更高的病理肿瘤分期、更高的分级和更大的肿瘤大小。此外,与没有这些组织病理学表现的患者相比,有肿瘤坏死的患者微血管侵犯和血小板增多症的出现更频繁。在多变量回归分析中,只有转移阶段、淋巴结受累、血小板计数>400/nl和肿瘤坏死对生存(CSS,OS)仍然具有显著意义。
根据结果,肿瘤坏死可能是RCC患者预后评估中的一个有用因素。建议将该参数纳入术后生存的预后模型中。